Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kaposi's sarcoma. New treatment modalities.

P Gascón1, R A Schwartz

  • 1Department of Hematology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, USA.

Dermatologic Clinics
|January 8, 2000
PubMed
Summary

New antiretroviral therapies are effectively treating Kaposi

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropilin-2 upregulation by stromal TGFβ1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth.

Neoplasia (New York, N.Y.)·2025
Same author

Role of semaphorins, neuropilins and plexins in cancer progression.

Cancer letters·2024
Same author

Epidemiological, Clinical, and Therapeutic Profile of Uveitis in Multiple Sclerosis: A Multicenter Study.

Ocular immunology and inflammation·2024
Same author

Acute macular neuroretinopathy after COVID-19 vaccine.

Journal francais d'ophtalmologie·2022
Same author

[Retinal arteriovenous communication: Report of two cases].

Journal francais d'ophtalmologie·2022
Same author

Role of en face OCT in following outer retinal folds after rhegmatogenous retinal detachment.

Journal francais d'ophtalmologie·2021

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Background:

  • Kaposi's sarcoma (KS) is a significant cause of illness and death in individuals with acquired immunodeficiency syndrome (AIDS), particularly affecting homosexual and bisexual men.
  • The AIDS epidemic has provided extensive experience and knowledge regarding Kaposi's sarcoma over the past two decades.

Purpose of the Study:

  • To review the evolving understanding and treatment of Kaposi's sarcoma in the context of the AIDS epidemic.
  • To highlight the impact of new antiretroviral therapies on the clinical course of Kaposi's sarcoma.
  • To discuss emerging experimental therapies targeting the pathogenesis of Kaposi's sarcoma.

Main Methods:

  • Review of accumulated knowledge and clinical experience with Kaposi's sarcoma over 20 years.
  • Analysis of the impact of novel antiretroviral therapies, including protease inhibitors, on Kaposi's sarcoma.
  • Examination of ongoing clinical trials for experimental Kaposi's sarcoma therapies.

Main Results:

  • New antiretroviral therapies, notably protease inhibitors, are leading to complete resolution and control of Kaposi's sarcoma in many cases.
  • Chemotherapy, especially liposomal preparations, remains a primary treatment, but new agents are emerging.
  • Experimental therapies such as angiogenesis inhibitors and immune modulators show promise.

Conclusions:

  • Advances in HIV treatment and novel therapeutic strategies offer optimism for the future management of Kaposi's sarcoma.
  • Targeting specific pathogenic pathways of Kaposi's sarcoma is a key focus for developing new treatments.
  • The clinical course of Kaposi's sarcoma is being positively altered by advancements in both HIV and cancer therapies.

Related Experiment Videos